pdufa.bio
Home › Decisions › AZN 2026-04-28

AZN FDA decision — Apr 28, 2026

✓ APPROVED

AstraZeneca PLC — BREZTRI AEROSPHERE (budesonide/glycopyrrolat · Asthma.

Run-up into the decision (T-120 → T+5)

PDUFA 4/28/26$209.48$162.311/11/25
Daily close, T-120 (11/11/25) through T+5. Run-up high $209.48 on 2/18/26, low $162.3 on 11/13/25 (T-120 to T-1). FDA decision 4/28/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-04-28
OutcomeApproved
Drug / candidateBREZTRI AEROSPHERE (budesonide/glycopyrrolat
CompanyAstraZeneca PLC
120-day run-up (T-120→T-1)+14.7%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio